Nonetheless, sevelamer did not affect levels of these metabolites, indicating that this drug does not improve insulin sensitivity and lipid levels by reverting concentrations of these metabolites in subjects with obesity to those in lean subjects. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.